Transmedics Group Stock Fair Value Calculator – The Manufacturers Life Insurance Company Sells Shares of TransMedics Group,
February 14, 2023
Trending News ☀️
Transmedics Group Stock Fair Value Calculator – TRANSMEDICS ($NASDAQ:TMDX): The Manufacturers Life Insurance Company recently sold shares of TransMedics Group, Inc. (“TransMedics”). TransMedics is a leading medical technology company that specializes in developing organ transplantation solutions. It offers a comprehensive suite of products and services designed to improve the outcomes of organ transplantation. The company’s products enable the preservation of organs at clinically relevant temperatures for longer durations, and its services support the entire organ transplantation process from pre-transplant evaluation to post-transplant recovery. TransMedics has developed the OCS Heart machine, which is used for heart transplants, as well as the OCS Lung machine for lung transplants. Both machines enable organs to be maintained at clinically relevant temperatures for up to several hours, allowing for successful transplants despite a lack of refrigeration.
The company has also developed a range of services, such as remote organ monitoring and post-transplant care. In addition to this, TransMedics is engaged in the development of a portfolio of next-generation organ preservation technologies. The company is focused on advancing the science of organ preservation and utilizing its expertise in organ transplantation to bring new treatments and technologies to the market. Overall, by selling shares of TransMedics, The Manufacturers Life Insurance Company has demonstrated its commitment to investing in innovative medical technologies that can improve patient outcomes. TransMedics’ cutting-edge products and services have the potential to revolutionize the field of organ transplantation and ultimately save many lives.
Price History
The media sentiment towards the stock has generally been neutral, with some optimism due to the potential of their products. On Monday, the TransMedics Group’s stock opened at $64.2 and closed at $68.0, representing a rise of 6.9% from the prior closing price of 63.7. This indicates that investors have been increasingly positive about the company’s prospects and future growth. TransMedics Group, Inc. develops and commercializes organ care systems which can be used to preserve, assess and transport organs such as hearts and lungs for transplantation. Their products aim to improve organ preservation and allow for better evaluation and transportation of organs.
The stock’s performance on Monday is an indication of investors’ confidence in TransMedics Group, Inc. and their products. With the potential of their products to improve organ preservation and transportation, investors have been showing increasing interest in investing in the company. Furthermore, with the company’s ability to launch new products in the near future, it is likely that the stock will continue to perform well in the market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Transmedics Group. More…
| Total Revenues | Net Income | Net Margin |
| 71.75 | -42.18 | -58.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Transmedics Group. More…
| Operations | Investing | Financing |
| -48.43 | 67.27 | 164.91 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Transmedics Group. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 274.87 | 87.02 | 1.82 |
Key Ratios Snapshot
Some of the financial key ratios for Transmedics Group are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 50.4% | – | -53.5% |
| FCF Margin | ROE | ROA |
| -84.7% | -20.1% | -8.7% |
Analysis – Transmedics Group Stock Fair Value Calculator
GoodWhale has conducted an analysis of TRANSMEDICS GROUP‘s fundamentals and found that the company is currently overvalued. According to GoodWhale’s proprietary Valuation Line, the fair value of TRANSMEDICS GROUP share is estimated to be around $46.1. But presently, the stock is trading at $68.0, a premium of 47.5%. GoodWhale has examined a range of financial factors, looking at the company’s profitability and cash flow, along with its balance sheet health. Additionally, GoodWhale has considered TRANSMEDICS GROUP’s future prospects and growth opportunities, as well as its competitive position in the market. Given the current market price, GoodWhale believes that investors should be cautious while investing in TRANSMEDICS GROUP. GoodWhale recommends that investors decide their investment approach based on their own risk appetite and financial goals. Furthermore, they should also look at other factors such as economic conditions, sectoral trends and management performance of the company before investing. More…
Peers
The company’s primary competitors are RxSight Inc, Motus GI Holdings Inc, Lucid Diagnostics Inc. All these companies are engaged in the development of technologies that would improve the outcomes of organ transplantation. While TransMedics Group Inc has a strong position in the market, its competitors are also gaining ground.
– RxSight Inc ($NASDAQ:RXST)
RxSight Inc. is a medical device company that develops and markets advanced artificial intelligence and machine learning software for the treatment of eye diseases. The company’s products are used by ophthalmologists and optometrists to improve patient outcomes and reduce costs. RxSight Inc. is headquartered in Irvine, California.
– Motus GI Holdings Inc ($NASDAQ:MOTS)
Motus GI Holdings Inc is a medical technology company that develops and commercializes gastrointestinal products. The company’s primary product is the Full Spectrum Endoscopy (FSE) system, which is a next-generation platform that provides improved visualization of the GI tract. Motus GI Holdings Inc also offers the CleanCide Wipe, a sanitizing product for endoscopes. The company has a market cap of 6.17M and a ROE of -183.03%.
– Lucid Diagnostics Inc ($NASDAQ:LUCD)
Lucid Diagnostics Inc is a medical diagnostic company that develops and commercializes proprietary technologies to provide clinicians with actionable information at the point of care. The company’s products include the Lucid Reader, a handheld device that delivers rapid and accurate results for a variety of common diagnostic tests; and the Lucid IQ, a cloud-based software platform that aggregates and analyzes data from multiple sources to provide real-time insights into patient health. Lucid Diagnostics Inc has a market cap of 72.12M as of 2022 and a Return on Equity of -67.45%.
Summary
TransMedics Group, Inc. is a promising investment opportunity for those who are looking to diversify their portfolio. Analysts have been fairly neutral in their sentiment towards the stock, but that hasn’t stopped the stock price from rising in recent days. The Manufacturers Life Insurance Company has recently started to sell shares of TransMedics Group, Inc., allowing for greater access to the stock and providing additional confidence for potential investors. Generally, investors who are prepared to take on a higher degree of risk may find TransMedics Group, Inc. to be an attractive option for their portfolio.
